These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11348705)

  • 1. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application.
    Betti M; Voltan R; Marchisio M; Mantovani I; Boarini C; Nappi F; Ensoli B; Caputo A
    Vaccine; 2001 May; 19(25-26):3408-19. PubMed ID: 11348705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
    Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
    Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
    Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
    J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
    Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
    AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins.
    Fraisier C; Abraham DA; van Oijen M; Cunliffe V; Irvine A; Craig R; Dzierzak EA
    Gene Ther; 1998 Jul; 5(7):946-54. PubMed ID: 9813666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant.
    Balboni PG; Bozzini R; Zucchini S; Marconi PC; Grossi MP; Caputo A; Manservigi R; Barbanti-Brodano G
    J Med Virol; 1993 Dec; 41(4):289-95. PubMed ID: 8106862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Criteria for selection of HIV vaccine candidates--general principles.
    Ensoli B
    Microbes Infect; 2005 Nov; 7(14):1433-5. PubMed ID: 16213181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction, expression and immunogenicity analysis of a Tat N-terminus-deleted mutant fusion protein of human immunodeficiency virus type 1].
    Zhang HQ; Liao WT; Chen QL; Ge YB; Yang J; Zhang PP; Qi PP; Liu C; He T; Wang JH; Pan W; Cao J
    Bing Du Xue Bao; 2011 Nov; 27(6):580-6. PubMed ID: 22263271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein.
    Siddappa NB; Venkatramanan M; Venkatesh P; Janki MV; Jayasuryan N; Desai A; Ravi V; Ranga U
    Retrovirology; 2006 Aug; 3():53. PubMed ID: 16916472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection.
    Huigen MC; Kamp W; Nottet HS
    Eur J Clin Invest; 2004 Jan; 34(1):57-66. PubMed ID: 14984439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients.
    Rossi C; Balboni PG; Betti M; Marconi PC; Bozzini R; Grossi MP; Barbanti-Brodano G; Caputo A
    Gene Ther; 1997 Nov; 4(11):1261-9. PubMed ID: 9425451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transactivation of heterologous promoters by HIV-1 tat.
    Han P; Brown R; Barsoum J
    Nucleic Acids Res; 1991 Dec; 19(25):7225-9. PubMed ID: 1662814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale behind a vaccine based on multiple HIV antigens.
    Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
    Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
    Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
    J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid.
    Le Buanec H; Lachgar A; Bizzini B; Zagury JF; Rappaport J; Santagostino E; Muça-Perja M; Gringeri A
    Biomed Pharmacother; 1998; 52(10):431-5. PubMed ID: 9921411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Tat vaccines.
    Ensoli B; Cafaro A
    Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
    [No Abstract]   [Full Text] [Related]  

  • 19. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
    Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
    Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.